論文

査読有り 最終著者
2018年6月1日

Cost-effectiveness of a new opportunistic screening strategy for walk-in fingertip HbA1c testing at community pharmacies in Japan

Diabetes Care
  • Aiko Shono
  • ,
  • Masahide Kondo
  • ,
  • Shuling Hoshi
  • ,
  • Reiko Okubo
  • ,
  • Naoya Yahagi

41
6
開始ページ
1218
終了ページ
1226
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2337/dc17-1307
出版者・発行元
American Diabetes Association Inc.

OBJECTIVE A new opportunistic community-based strategy was launched in Japan in April 2014 to detect lifestyle-related diseases, including diabetes, by creating Specimen Measurement Offices (SMOs). SMOs offer walk-in fingertip HbA1c testing. This article aimed to assess the value-for-money of HbA1c testing services at SMOs by conducting a cost-effectiveness analysis. RESEARCH DESIGN AND METHODS We compared two scenarios: 1) status quo, defined as HbA1c testing that is available only through conventional screening, and 2) HbA1c testing available at SMOs as a complement to the status quo scenario. The model consisted of a screening module with a decision tree and a disease progression module with a Markov model. We calculated incremental cost-effectiveness ratios (i.e., cost per quality-adjusted lifeyears [QALYs]) over the lifetime analytic horizon as the primary end point of the cost-effectiveness analysis. In this model, we assumed the participant cohort to be people 40-74 years of age who sought walk-in fingertip HbA1c testing at SMOs on the premises of community pharmacies. Costs and outcomes were discounted at a rate of 3%. The cost-effectiveness was analyzed from a societal perspective. RESULTS The incremental cost per individual for those 40-74 years of age was estimated to be 2527 U.S. dollars (USD) (252,722 Japanese yen [JPY]) for HbA1c testing at SMOs compared with the status quo. Incremental effectiveness was estimated to be 0.0203 QALYs for HbA1c testing at SMOs compared with the status quo. Therefore, this cost-effectiveness analysis showed that compared with the status quo, HbA1c testing at SMOs was more effective and had lower cost for the population studied. CONCLUSIONS We consider our results to be robust because most simulations were under the threshold of USD 50,000 (JPY 5,000,000) per QALYs gained, by sensitivity analysis. These results will be useful to managers of pharmacies or other health institutions and/or policy makers in local government.

リンク情報
DOI
https://doi.org/10.2337/dc17-1307
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29686159
ID情報
  • DOI : 10.2337/dc17-1307
  • ISSN : 1935-5548
  • ISSN : 0149-5992
  • PubMed ID : 29686159
  • SCOPUS ID : 85047481855

エクスポート
BibTeX RIS